Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PROCEPT BioRobotics (PRCT) Depreciation & Amortization (CF) (2020 - 2025)

Historic Depreciation & Amortization (CF) for PROCEPT BioRobotics (PRCT) over the last 6 years, with Q3 2025 value amounting to $1.6 million.

  • PROCEPT BioRobotics' Depreciation & Amortization (CF) rose 2183.73% to $1.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.1 million, marking a year-over-year increase of 2029.81%. This contributed to the annual value of $5.2 million for FY2024, which is 3748.36% up from last year.
  • PROCEPT BioRobotics' Depreciation & Amortization (CF) amounted to $1.6 million in Q3 2025, which was up 2183.73% from $1.6 million recorded in Q2 2025.
  • Over the past 5 years, PROCEPT BioRobotics' Depreciation & Amortization (CF) peaked at $1.6 million during Q3 2025, and registered a low of $642000.0 during Q2 2023.
  • Over the past 5 years, PROCEPT BioRobotics' median Depreciation & Amortization (CF) value was $915000.0 (recorded in 2021), while the average stood at $1.0 million.
  • As far as peak fluctuations go, PROCEPT BioRobotics' Depreciation & Amortization (CF) plummeted by 1715.85% in 2022, and later skyrocketed by 9879.34% in 2023.
  • PROCEPT BioRobotics' Depreciation & Amortization (CF) (Quarter) stood at $763000.0 in 2021, then fell by 13.11% to $663000.0 in 2022, then surged by 98.79% to $1.3 million in 2023, then rose by 10.24% to $1.5 million in 2024, then grew by 11.36% to $1.6 million in 2025.
  • Its Depreciation & Amortization (CF) was $1.6 million in Q3 2025, compared to $1.6 million in Q2 2025 and $1.5 million in Q1 2025.